Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EpiCept has received fast track designation for AmiKet (amitriptyline 4%, ketamine 2% cream) from the US Food and Drug Administration (FDA).
Subscribe to our email newsletter
AmiKet is indicated for the treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy in patients previously treated with taxane-based chemotherapy.
According to the FDA, products with a fast track designation oftentimes receive priority review, which may reduce the standard review time by half.
EpiCept president and chief executive officer Jack Talley said: "We expect the receipt of this designation will prove to be highly valuable in our current partnering efforts for AmiKet".